Best Startup
At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United States based Vice President operating in the Pharmaceutical space. If you think a Vice President is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Ron Alfa
Senior Vice President, Translational Discovery of Recursion Pharmaceuticals
Ron Alfa is Vice President, Discovery and Product at Recursion Pharmaceuticals where he manages scientific product development and external alliances across Recursion’s AI-enabled discovery platform. Ron Alfa’s scientific contributions prior to Recursion span Neurosciences, Metabolism, and Genetics.
Follow Ron Alfa:
About Recursion Pharmaceuticals: Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Mark Mallon
Executive Vice President, Global Product and Portfolio Strategy, Medical Affairs and Corp. Affairs of AstraZeneca
Mark Mallon is responsible for the growth and performance of AstraZeneca’s International region, which predominantly includes AstraZeneca’s commercial businesses in Asia Pacific, Russia, Latin America, the Middle East and Africa. Most recently, Mark served as Regional Vice President for Asia Pacific where he was accountable for the growth and performance of the AstraZeneca business in 14 markets. While in this role Mark has also served as President of AstraZeneca China, responsible for the company’s overall operations in China and Hong Kong. Previously, Mark led the marketing, sales and commercial operations for AstraZeneca K. K. (Japan). Since joining AstraZeneca in 1994, Mark has held a number of additional leadership roles, Including Marketing Company President of the AstraZeneca Italian subsidiary company and Vice President of Marketing and Sales Operations of AstraZeneca’s US business. While in the US, Mark also was a Board Member for the Christiana Care Network, one of the the largest healthcare networks on the East Coast. Mark received a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and an MBA in Marketing and Finance from the Wharton School of Business. He is based in Shanghai.
Follow Mark Mallon:
About AstraZeneca, NeoGenomics: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
Raymond H. Diradoorian
Executive Vice President of Allergan
Mr. Diradoorian has been Executive Vice President, Global Technical Operations since February 2006. From April 2005 to February 2006, Mr. Diradoorian served as Senior Vice President, Global Technical Operations. Since February 2001, Mr. Diradoorian served as Vice President, Global Engineering and Technology. Mr. Diradoorian joined Allergan in July 1981. Prior to joining Allergan, Mr. Diradoorian held positions at American Hospital Supply and with the Los Angeles Dodgers baseball team. Mr. Diradoorian received a Bachelor of Science degree in Biological Sciences from the University of California, Irvine and a Master of Science degree in Technology Management from Pepperdine University.
Follow Raymond H. Diradoorian:
About Allergan: Allergan is a global pharmaceutical company.
Stephen Barat
Associate Vice President, Non-Clinical Development of Allergan
Stephen Barat is currently the Executive Director of Non-clinical and Translational Sciences – Safety Assessment and Bioanalysis for Allergan. He has 20 years of experience in global drug development and registration, with a specific interest in drug device combinations, the interface of safety assessment and CMC requirements, and extensive experience in the safety assessment of impurities. Dr. Barat is a member of the PQRI – PDP working group and toxicology sub-team as well as the USP Expert Panel for Biocompatability of Packaging Materials.
Follow Stephen Barat:
About Allergan, The Janssen Pharmaceutical Companies of Johnson & Johnson: Allergan is a global pharmaceutical company.
RJ Fitch
Vice President Operations & General Manager of WuXi AppTec
Innovative senior management leader Raymond J. “RJ” Fitch possesses more than two decades of experience in the biotech and global healthcare industries. As the Vice President of Operations & General Manager for WuXi AppTec Advanced Therapies, Mr. Fitch leverages his knowledge of site operations and supply chain functions to oversee logistics operations, biological testing services, engineering, and other operations at the company’s Philadelphia location. RJ Fitch is responsible for three facilities within the Philadelphia site. Mr. Fitch began his career more than 20 years ago, graduating from Philadelphia University with a bachelor of science in biology. After working for Merck & Company, he joined Sanofi Pasteur as a director of vaccine aseptic filling & formulation. He stayed with the company for seven years, rising through the ranks to become the senior director of influenza viral manufacturing. Mr. Fitch later served as the associate vice president at Genzyme, a Sanofi company, and vice president of Sanofi Pasteur in Toronto, Canada. During his time with Sanofi Pasteur, RJ Fitch returned to school to earn an executive MBA from the New York University Stern School of Business.
Follow RJ Fitch:
About WuXi AppTec: WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical.
Axel Hoos
Senior Vice President, Therapeutic Area Head of GSK
Axel Hoos oversees both its discovery and development functions and builds the Oncology portfolio of GSK across several modalities including antibodies, small molecules, bispecific molecules and cell & gene therapies. The TA’s scientific focus is on Immuno-Oncology, Epigenetics and Cell Therapy. Axel Hoos also serves on the Scientific Advisory Board of the HIV Cure Center, a co-venture of GSK and the University of North Carolina at Chapel Hill. Axel Hoos further serves as Executive Chairman of the Board of Trustees of the Sabin Vaccine Institute (SVI), a Global Health organization, Non-executive Director on the Board of Imugene, a biotech company, Co-Chairman of the Cancer Immunotherapy Consortium (CIC) and Scientific Advisory Board Member of the Cancer Research Institute (CRI). Previously, Axel Hoos was the Global Medical Lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy in Immuno-Oncology.
Follow Axel Hoos:
About GSK: GSK Venture Fund is a Massachusetts-based venture capital fund focused on investments within the area of bioelectronics.
Jared Kohler
Sr. Vice President, Project Management & Data Science Operations & Precision for Medicine of Precision for Medicine
Jared Kohler is the Sr. Vice President, Project Management & Data Science Operations, Precision for Medicine at Precision for Medicine.
Follow Jared Kohler:
About Precision for Medicine, Quartz Bio: Precision for Medicine is a specialized scientific services company helping life science innovators develop medical products.
Merry Lee
Vice President, Medical Device Regulatory Strategy of Precision for Medicine
Merry Lee Bain is the Vice President, Medical Device Regulatory Strategy at Precision for Medicine.
Follow Merry Lee:
About Precision for Medicine: Precision for Medicine is a specialized scientific services company helping life science innovators develop medical products.
Alex Gourlay
Executive Vice President of Walgreens
Alex Gourlay joined Walgreens as Executive Vice President, President of Customer Experience and Daily Living in October 2013. In this new role, reporting to Walgreens President and Chief Executive Officer Greg Wasson, he leads an enhanced Walgreens daily living business operation overseeing customer experience, U.S. merchandising, marketing, customer insights, daily living products and promotions. Alex was previously Chief Executive, Health & Beauty Division, Alliance Boots, a role he undertook in January 2009, when he was also appointed to the Board of Alliance Boots. He had previously been Managing Director of Boots UK and a member of the Alliance Boots Group operating committee following the acquisition of Alliance Boots plc by AB Acquisitions Limited in 2007. Prior to this, he was Healthcare Director of Boots the Chemists, having held senior management positions in store operations and human resources.
Follow Alex Gourlay:
About Walgreens, Walgreens Boots Alliance: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Kathleen Wilson-Thompson
Senior Vice President & Chief Human Resources Officer of Walgreens
Kathleen Wilson-Thompson is Senior Vice President & Chief Human Resources Officer at Walgreen Co.
Follow Kathleen Wilson-Thompson:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Rob Ewing
Regional Vice President of Walgreens
Rob Ewing is a Regional Vice President at Walgreens.
Follow Rob Ewing:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Abhi Dhar
Senior Vice President, Chief Information Officer of Walgreens
Abhi Dhar is senior vice president and chief information officer for Walgreen Co. based in Deerfield, Illinois. He is responsible for leading the information technology function and the company’s consumer-facing digital product and innovation efforts. He serves as a member of the Walgreens Enterprise Operating Committee with accountability for technology within the division. Prior to this role Dhar led the rapidly growing and award-winning mobile product/services business and simultaneously was responsible for end-to-end delivery, software development and technology innovation for the digital division within Walgreens. Dhar joined Walgreens in 2009 as group vice president and chief technology officer. Previously, he served as chief information officer (CIO) and senior vice president at TravelCLICK from 2006 to 2009, where he built a global IT and product delivery organization by restructuring the organization, recruiting top talent and optimizing vendor relationships. From 2001 to 2006, he held various top technology leadership roles with Cendant Corporation and its Travelport division. Dhar also worked in engineering and digital/online consulting capacities with PricewaterhouseCoopers and AT&T. Dhar earned an undergraduate degree in engineering from the National Institute of Engineering, Mysore University in India in 1993 and earned a master of science degree in engineering from the New Jersey Institute of Technology in 1995.
Follow Abhi Dhar:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Luke Rauch
Group Vice President, Customer Experience & General Manager, Owned Brands of Walgreens
Luke Rauch is the Group Vice President, Customer Experience & General Manager, Owned Brands at Walgreens.
Follow Luke Rauch:
About Walgreens: Walgreens provides multi-channel access to consumer goods and cost-effective pharmacy, health, and wellness services.
Karen Ling
Senior Vice President & Chief Human Resources Officer of Forest Laboratories
Prior to joining Actavis, Ms. Ling served as Senior Vice President and Chief Human Resources Officer for Forest Laboratories, Inc. Ms. Ling joined Forest in January 2014 from Merck & Co., Inc., where she served as Senior Vice President, Human Resources, for the company’s Global Human Health and Consumer Care businesses worldwide. Prior to that role at Merck, she was Vice President, Compensation and Benefits. Before Merck, Ms. Ling was Group Vice President, Global Compensation & Benefits at Schering-Plough. She also spent 14 years at Wyeth in various positions of responsibility in human resources as well as in Wyeth Pharmaceutical’s Labor and Employment Department. Prior to joining Wyeth, Ms. Ling practiced corporate law with Goldstein and Manello, P.C. in Boston. Ms. Ling holds a B.A. from Yale University and a J.D. from Boston University School of Law.
Follow Karen Ling:
About Allergan, Forest Laboratories: Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships.
Marco Taglietti
Executive Vice President of Forest Laboratories
Dr. Taglietti is Executive Vice President, Drug Development and Research, and Chief Medical Officer of Forest Laboratories, Inc. He continues to be President of the Forest Research Institute. He previously served as Senior Vice President—Research and Development of the Company and President, Forest Research Institute, Inc. from December 2010 to December 2013. Prior thereto, Dr. Taglietti served as Vice President—Research and Development from December 2008 to December 2010. Dr. Taglietti joined Forest in August 2007 as Executive Vice President—Research and Development and Chief Medical Officer of Forest Research Institute, Inc. Prior to joining Forest, Dr. Taglietti was Senior Vice President and Head of Global Research and Development at Stiefel Laboratories for three years. Prior to that, Dr. Taglietti was at Schering-Plough Corporation for twelve years in positions of increasing responsibility including Vice President—Worldwide Clinical Research for Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti received his medical degree and board certifications from the University of Pavia in Italy.
Follow Marco Taglietti:
About Forest Laboratories, SCYNEXIS: Forest Laboratories, Inc. (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships.
Shannon Richey
Vice President & General Manager, Asterand Bioscience Detroit Operations of BioIVT
Follow Shannon Richey:
About Asterand, BioIVT: BioIVT is a worldwide provider of biological and in vitro products to pharmaceutical and biotechnology organizations
Tim Tompkins
Vice President & Deputy Chief Information Security Officer of CVSHealth
Vice President & Deputy Chief Information Security Officer at CVS Health.
Follow Tim Tompkins:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Jonathan C. Roberts
President Caremark Pharmacy Services and Executive Vice President of CVS Caremark Caremark of CVSHealth
President Caremark Pharmacy Services and Executive Vice President of CVS Caremark Caremark at CVS Caremark Corporation
Follow Jonathan C. Roberts:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Papatya Tankut
Vice President, Pharmacy Affairs of CVSHealth
Papatya Tankut is Vice President of Pharmacy Affairs for CVS Health. Tankut is responsible for engaging with nonprofit, governmental and health-based organizations to expand CVS Health’s efforts to improve and enhance pharmacy care. Tankut began her career as a pharmacist at CVS/pharmacy in 1994. She has held various positions within the organization, including Vice President of Pharmacy Professional Services; Director, Pharmacy Recruiting and Professional Relations; and Manager of Professional and College Relations. In those roles she helped develop the company’s pharmacist recruitment strategies and initiatives, and oversaw the regulatory compliance, quality assurance and patient safety, and retail clinical services departments. Tankut graduated from the University of Maryland School of Pharmacy.
Follow Papatya Tankut:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Stephen J. Gold
Executive Vice President & Chief Information Officer of CVSHealth
Stephen Gold is Executive Vice President and Chief Information Officer for CVS Health. In this role since July 2012, Gold is the company’s senior technology executive and has responsibility for all information systems and technology operations, including information technology strategy, application development, technology infrastructure, and business and technology operations. A seasoned executive with more than 30 years of information systems management experience, Gold was previously Senior Vice President and CIO for Avaya, guiding all aspects of the company’s technology strategy, as well as leading IT business operations and systems globally. Prior to joining Avaya, Gold was the Executive Vice President, Chief Information Officer and Corporate Chief Technology Officer for GSI Commerce. At GSI, Gold was responsible for product development, product marketing, systems architecture, product engineering and technology operations for one of the nation’s premier eCommerce solutions providers, supporting brands such as Toys R Us, Polo, BCBG, Estee Lauder, Kate Spade and all major sports leagues. Gold holds an undergraduate degree in computer science from Saint John’s University and currently serves as a member of their advisory board.
Follow Stephen J. Gold:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Robert (Rocky) O. Kraft
Executive Vice President of CVSHealth
Rocky Kraft is the President at Omnicare Inc.
Follow Robert (Rocky) O. Kraft:
About CVSHealth, Omnicare, Omnicare: CVS Health provides an integrated healthcare services offering for its members.
Troyen Brennan, M.D.
Executive Vice President and Chief Medical Officer of CVSHealth
Troyen A. Brennan, M.D., M.P.H., is Executive Vice President and Chief Medical Officer of CVS Health. In this role, Brennan provides oversight for the development of CVS Health’s clinical and medical affairs and health care strategy, as well as the company’s MinuteClinic and Accordant Health Care businesses. Previously, Brennan was Chief Medical Officer of Aetna Inc., where he was responsible for clinical policies, as well as Aetna’s full range of clinical operations, disease management programs and patient management services. Prior to that, Brennan served as president and CEO of Brigham and Women’s Physicians Organization. In his academic work, he was Professor of Medicine at Harvard Medical School and Professor of Law and Public Health at Harvard School of Public Health. Brennan received his M.D. and M.P.H. degrees from Yale Medical School and his J.D. degree from Yale Law School. He has a Master’s Degree from Oxford University, where he was a Rhodes Scholar. He earned a BS from Southern Methodist University. He completed his internship and residency in internal medicine at Massachusetts General Hospital. He is a member of the Institute of Medicine of the National Academy of Sciences.
Follow Troyen Brennan, M.D.:
About CVSHealth: CVS Health provides an integrated healthcare services offering for its members.
Franklin Maddux
Chief Medical Officer and Executive Vice President for Clinical and Scientific Affairs of Fresenius Medical Care North America
Franklin W. Maddux, is the Executive Vice President for Clinical and Scientific Affairs and Chief Medical Officer of Fresenius Medical Care. Frank joined us in 2009 after Fresenius Medical Care acquired a company he founded, Health IT Services Group, a leading-edge Electronic Health Record (EHR) software company. Frank has more than 25 years of health-care experience, including the practice of nephrology. He is a founder of Specialty Care, a leading provider of perfusion and surgical support services. Frank also serves as Clinical Associate Professor of Medicine at the University of North Carolina School of Medicine and formerly practiced nephrology at the Danville (Virginia) Urologic Clinic, serving as its president from 1995 to 2005. He has served on numerous boards and committees involved in developing technology initiatives in both the medical and regional economic development arenas. He received his bachelor’s degree in mathematics from Vanderbilt and an MD degree from the University of North Carolina at Chapel Hill, where he completed his internship, residency, chief residency and nephrology fellowship.
Follow Franklin Maddux:
About Fresenius Medical Care North America: Fresenius Medical Care North America provides healthcare services to people with renal and other chronic conditions.
Lisa Wyman
Vice President Quality of Acceleron Pharma
Follow Lisa Wyman:
About Acceleron Pharma: Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Chris Lento
Vice President of Commercialization of Pear Therapeutics
Follow Chris Lento:
About Pear Therapeutics: Pear Therapeutics is a software-based digital therapeutics platform designed to treat disease and enhance the efficacy of pharmaceuticals.
Jeffrey Mathers
Vice President, Commercial Technology, Software Engineering, R&D Platforms, and Architecture of Johnson & Johnson
Follow Jeffrey Mathers:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Vaibhav Narayan
Vice President, Digital Health Innovation of Johnson & Johnson
Follow Vaibhav Narayan:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Ravi Parameswar
Vice President, Head of Global Strategic Insights & Analytics of Johnson & Johnson
Follow Ravi Parameswar:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Nicholas Pachuda
Worldwide Vice President,Orthopedic Innovation,External Innovation & Enabling technologies of Johnson & Johnson
Follow Nicholas Pachuda:
About Johnson & Johnson, Peptilogics: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Amy Foley
Vice President, Product Innovation & Delivery of Johnson & Johnson
As Vice President of Product Innovation & Delivery, Amy Foley leads the Johnson & Johnson portfolio of health and wellness capabilities, including new product and service innovation, creation, implementation, operations, customer service and compliance and quality.
Follow Amy Foley:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Jane Adams
Vice President, Federal Government Affairs of Johnson & Johnson
Follow Jane Adams:
About Johnson & Johnson, Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Hartmuth Kolb
Vice President, Neuroscience Biomarkers and Janssen R&D Global Imaging of Johnson & Johnson
Follow Hartmuth Kolb:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Cat Oyler
Vice President, Global Public Health, Tuberculosis of Johnson & Johnson
Cat Oyler serves as vice-president of global public health (GPH) at Johnson & Johnson (J&J), leading the tuberculosis (TB) focus area strategy team (FAST), and as a member of the GPH executive leadership team. In this role, Cat leads the enterprise TB FAST to deliver on J&J’s aspiration to create a world without tuberculosis through ending mortality from multidrug-resistant tuberculosis. Cat previously served as global head of strategy and operations for J&J Innovation (JJI). She had responsibility for aligning the World Without Disease Accelerator, Lung Cancer Initiative, and JJI organizations to accelerate innovation in order to prevent, intercept and cure disease. Before this, Cat held the role of vice-president of strategy and external innovation for Janssen Research and Development, the global R&D arm of Janssen Pharmaceutical Companies of Johnson & Johnson. Here, she directed the development of the company’s long-term ‘A World Without Disease’ strategy, focusing on transforming human health. Additionally, Cat is an Aspen Institute First Mover Fellow and serves as executive sponsor for the university workstream for Women in Science, Technology, Engineering, Math, Manufacturing, and Design (WiSTEM2D).
Follow Cat Oyler:
About Johnson & Johnson: Johnson & Johnson engages in the research and development, manufacture and sale of a range of products in the healthcare field.
Asish Xavier
Vice President, Venture Investments of Johnson & Johnson Development Corporation
Asish Xavier is the Vice President of Venture Investments at joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2004. Asish is based in Silicon Valley, California. Asish previously worked in business development at BioRexis Pharmaceutical, Inc., which was acquired by Pfizer in 2007. While at BioRexis, Asish assisted the company in raising a $30 million second round of financing. Asish has worked in business development at Structural GenomiX, Inc., acquired by Eli Lilly in 2008, and was a project leader at Message Pharmaceuticals, Inc. Asish received a Ph.D. from the University of Houston and a Master of Business Administration from the Wharton School of the University of Pennsylvania, where he graduated with honors. Asish received a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. Asish was also a postdoctoral research Fellow in the Department of Chemistry at Johns Hopkins University.
Follow Asish Xavier:
About Cue, ESCAPE Bio, Johnson & Johnson Development Corporation, Legend Biotech, Paige, ViaCyte, XWPharma: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Marian Nakada
Vice President, Venture Investments of Johnson & Johnson Development Corporation
Marian Nakada, PhD, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in Boston, MA. Previously, Dr. Nakada was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy. Dr. Nakada joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Dr. Nakada joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor’s technologies were competitive with the industry. Dr. Nakada has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.
Follow Marian Nakada:
About Johnson & Johnson Development Corporation, Women in VC: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Kadir Kadhiresan
Vice President, Venture Investments of Johnson & Johnson Development Corporation
V. Kadir Kadhiresan, PhD, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2007 and focuses on investments in medical devices and digital health. Kadir has more than two decades of operational, investment and business development experience. Based in Boston, Kadir works closely with Johnson & Johnson leadership to identify business needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), Neotract (Acquired by Teleflex) and Inspire Medical Systems (NYSE: INSP). Before joining JJDC, Kadir was head of Business Development at Guidant, Inc., now Boston Scientific, Inc., where he led several transactions to access novel medical device technologies.
Follow Kadir Kadhiresan:
About Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Stacy Feld
Vice President, Consumer Venture Investments of Johnson & Johnson Development Corporation
Stacy received a B.A. in sociology, graduating magna cum laude from the University of Pennsylvania and earned her J.D. from Vanderbilt Law School.
Follow Stacy Feld:
About Johnson & Johnson Development Corporation, Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Tara O’Meara
Vice President, Clinical Development Operations of Bluebird Bio
Tara O’Meara is the Vice President of Clinical Development Operations at bluebird bio. Tara oversees a team responsible for the execution and analysis of bluebird bio’s lentiviral vector based gene therapy development programs. Currently bluebird bio has 4 active programs using ex vivo gene therapy for: cerebral adrenoleukodystrophy, transfusion dependent thalassemia, sickle cell disease and multiple myeloma. bluebird’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy as a one-time treatment option for patients with severe genetic and rare diseases and cancer. Prior to joining bluebird, Tara ran multiple clinical trials in 2 other rare diseases, LAL Deficiency and Pompe disease. Tara served as the clinical project manager for the clinical trials that were used as the basis for the regulatory submissions that led to the approval of Myozyme™ in the United States, Europe, and more than 40 additional countries worldwide. Tara has also been responsible for everything from small Phase II trials to very large, global Phase III trials in multiple therapeutic areas, including rare inherited diseases. Tara holds a BS in biology and a minor in women’s studies from Tufts University.
Follow Tara O’Meara:
About Bluebird Bio: Bluebird Bio offers products based on the transformative potential of gene therapy for patients with genetic and orphan diseases.
Ismail Kola
Executive Vice President & President UCB NewMedicines of UCB
Dr. Kola has served as our Director since October 18, 2010. Dr. Kola currently serves as Executive Vice President of UCB S.A. in Belgium, a biopharmaceutical company dedicated to the development of innovative medicines focused on the fields of central nervous system and immunology disorders, and also serves as President of UCB New Medicines, UCB’s discovery research through proof-of-concept organization, since November 2009. Since March 2007, Dr. Kola was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, and Chief Scientific Officer at Schering-Plough Corporation. Previously, Dr. Kola held senior positions commencing in 2003 at Merck & Company, where he was Senior Vice President and Site Head, Basic Research, and responsible for atherosclerosis and cardiovascular diseases, diabetes, obesity, infectious diseases, immunology and rheumatology, animal pharmacology and basic and medicinal chemistry. Prior to that, Dr. Kola was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporation, and served as consultant to SmithKline Beecham Pharmaceuticals, where he was also a member of the Genomics Advisory Board. During his tenure of proven leadership at several major pharmaceutical companies, Dr. Kola has overseen the successful development of numerous innovative new medicines, including products in the fields of diabetes, cancer, cardiovascular diseases and central nervous system disorders.
Follow Ismail Kola:
About UCB: UCB Pharma is a biopharmaceutical and specialty chemical company.
John DeYoung
Vice President of Worldwide Business Development of Pfizer
John DeYoung is Vice President of Worldwide Business Development for Pfizer Oncology. He is a member of the Oncology Leadership Team and the Worldwide Business Development Leadership Team. John joined Pfizer in 1991 and has held leadership positions in Finance, Marketing, Commercial Development and Business Development. He received a bachelor’s degree in business from Michigan State University and an M.B.A. from the University of Chicago.
Follow John DeYoung:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Morten Sogaard
Vice President and Head, Target Sciences of Pfizer
Follow Morten Sogaard:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Frank S Walsh
Executive Vice President of Pfizer
Frank is an accomplished Pharma and Biotech senior executive with over 20 years experience. Between 2002 and 2009, he was with Wyeth (Collegeville PA, USA), where he served as Executive Vice President and Head of Discovery Research Worldwide. This involved managing more than 1500 scientists across seven sites globally and delivering multiple products in diverse areas to IND and late stage clinical trials. Prior to joining Wyeth, Frank was at GlaxoSmithKline (UK) where he was Senior Vice President and Head of the Neurology Centre of Excellence for Drug Discovery. From 1997 to 2000, he was Vice President and Head of Neuroscience Research at SmithKline Beecham (UK). Before moving to industry, Frank had a distinguished academic career, during which he authored over 200 scientific publications. He was the Research Dean at the United Medical and Dental Schools of Guys and St. Thomas’ Hospitals (London, UK), and also the Sir William Dunn Professor of Experimental Pathology and previously worked at the Institute of Neurology Queen Square, London. He has honorary degrees from the University of Perugia, University of Bologna, University of Strathclyde and University of Dundee. He is a Fellow of King’s College London, a Fellow of the Academy of Medical Sciences London and a Corresponding Fellow of the Royal Society of Edinburgh.
Follow Frank S Walsh:
About OSSIANIX, Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Sonal Bhatia
Vice President, North America Medical Lead of Pfizer
Follow Sonal Bhatia:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Hakan Sakul
Vice President and Head of Diagnostics of Pfizer
Follow Hakan Sakul:
About Pfizer: Pfizer provides access to safe and effective and affordable medicines and health care services.
Micah Bregman
Vice President, Global Strategy and Pipeline, Allergan Aesthetics of AbbVie
Micah Bregman is the Vice President, Global Strategy and Pipeline at Allergan Aesthetics, AbbVie
Follow Micah Bregman:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Philip Hajduk
Vice President of AbbVie
Follow Philip Hajduk:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Azita Saleki Gerhardt
Senior Vice President, Operations of AbbVie
Azita Gerhardt is the SVP and President, Operations at AbbVie.
Follow Azita Saleki Gerhardt:
About AbbVie: AbbVie is a pharmaceutical company that discovers, develops, and markets both biopharmaceuticals and small molecule drugs.
Stephan Gotthardt
Senior Vice President Europe Supply Chain of Teva Pharmaceutical Industries
Stephan Gotthardt is the Senior Vice President Europe Supply Chain at Teva.
Follow Stephan Gotthardt:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Arthur Levin
Executive Vice President, Research & Development of Avidity Biosciences
Arthur A. Levin, Ph.D., is miRagen’s Executive Vice President of Research and Development. Dr. Levin is a drug development veteran having spent more than 30 years in the pharmaceutical industry, of which more than 15 years were in the area of research and development of RNA-targeting therapeutics. He is a recognized world expert on the preclinical and clinical development of oligonucleotide-based therapeutics. Prior to joining miRagen Therapeutics, Dr. Levin was Chief Development Officer of Santaris Pharma A/S, where he led the efforts on the first microRNA-targeting therapeutic in Phase 2 clinical trials, miravirsen. Before joining Santaris Pharma, Dr. Levin consulted for leading biotechnology companies, conducting research and development in RNA-based therapies such as mRNA, microRNA, and siRNA.Prior to consulting, Dr. Levin was Senior Vice President of Development at Isis Pharmaceuticals, where he was responsible for the drug development of Isis’ products across a range of therapeutic areas. His expertise was instrumental in advancing more than a dozen oligonucleotide drugs from basic research to clinical development in areas such as neuromuscular diseases, infectious diseases, metabolic disorders, cardiovascular disease, and cancer. He joined Isis from Hoffmann-La Roche Inc., where he was Research Leader. Dr. Levin holds a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry, New York, and a B.S. in Biology from Muhlenberg College.He completed his post-doctoral work at the Chemical Industry Institute of Toxicology in Research Triangle, North Carolina. He was the recipient of the Scala Award for Industrial Toxicology and is the author of more than 50 papers and book chapters.
Follow Arthur Levin:
About Avidity Biosciences, Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Andy Geall
Vice President of Formulations and Chemistry of Avidity Biosciences
Andy Geall is the VP of formulations and chemistry at Avidity Biosciences.
Follow Andy Geall:
About Avidity Biosciences: Avidity Biosciences is a biotech company that delivers nucleic acid therapeutics against genetic drivers of disease.
Kathryn E. Falberg
Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals
Kathryn Falberg was appointed our Executive Vice President and Chief Financial Officer in March 2012. She served as our Senior Vice President and Chief Financial Officer from 2009 to 2012. Her responsibilities include finance, strategy, corporate development and IT. From 1995 through 2001, Kathryn Falberg was with Amgen, Inc., where she served as Senior Vice President Finance, Strategy and Chief Financial Officer, and before that as Vice President, Controller and Chief Accounting Officer, and Vice President, Treasurer. From 2001 through 2008, Kathryn Falberg was President of Canyon Capital & Consulting, a private investment and consulting firm, where she worked with a number of smaller companies while also serving as a corporate director and audit committee chair for several companies. From February to November 2009, she was Chief Financial Officer and Chief Operating Officer at ARCA biopharma, Inc., a biopharmaceutical company. Kathryn Falberg received an M.B.A. and B.A. in Economics from the University of California, Los Angeles and is a Certified Public Accountant (inactive). Kathryn Falberg currently serves on the boards, and is chair of the audit committees, of biopharmaceutical companies Halozyme Therapeutics, Inc. and Medivation, Inc.
Follow Kathryn E. Falberg:
About Jazz Pharmaceuticals: Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments.
Steven Fasman
Senior Vice President & General Counsel of Catalent Pharma Solutions
Steven Fasman is Senior VP & General Counsel at Catalent Pharma Solutions.
Follow Steven Fasman:
About Catalent Pharma Solutions, Jewish Board of Family and Children’s Services: Catalent provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies.
Daniel Van Plew
Executive Vice President and General Manager, Industrial Operations and Product Supply of Regeneron
Daniel Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since July 2007. He joined the company in July 2007 and previously served as Senior Vice President, Vice President, and General Manager, Industrial Operations and Product Supply.
Follow Daniel Van Plew:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Bari Kowal
Senior Vice President, Head Development Operations & Portfolio Management of Regeneron
Follow Bari Kowal:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Goncalo Abecasis
Vice President of Regeneron
Follow Goncalo Abecasis:
About Regeneron, University of Michigan: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Ned Braunstein
Senior Vice President, Regulatory Affairs of Regeneron
Follow Ned Braunstein:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Hanne Bak
Senior Vice President Preclinical Manufacturing and Process Development of Regeneron
Follow Hanne Bak:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
David Weinreich
Executive Vice President, Head, Global Clinical Development of Regeneron
Follow David Weinreich:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Aris Baras
Senior Vice President, Regeneron Pharmaceuticals, General Manager, Regeneron Genetics Center of Regeneron
Aris Baras serves as Vice President and Head of the Regeneron Genetics Center (RGC), one of the largest human genetics programs in the world, spanning large-scale sequencing, informatics, and translational sciences using human genetics to advance and guide the development of Regeneron’s pipeline of important new medicines. He has established and leads several foundational genomics collaborations, such as with the Geisinger Health System to sequence at least 250,000 participants and with the UK Biobank to sequence 500,000 participants. The RGC has produced many high impact discoveries identifying new drug targets, validating existing development programs, and contributing important new gene discoveries. The RGC has sequenced more than 250,000 individuals to date, collaborating with more than 50 institutions around the world. Previously, Aris Baras held roles and responsibilities at Regeneron across R&D and business development. Prior to Regeneron, Aris Baras contributed to other biotechnology ventures and conducted research spanning antibody based therapeutics, cancer research, and nanotechnology applications in drug development. Aris Baras received his Bachelor’s of Science, M.D., and M.B.A., all from Duke University.
Follow Aris Baras:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Joseph LaRosa
Executive Vice President, General Counsel and Secretary of Regeneron
Follow Joseph LaRosa:
About Regeneron: Regeneron Pharmaceuticals is a biotechnology company that invents life-transforming medicines for people with serious diseases.
Juan Andres
Senior Vice President Technical Development, Manufacturing and Quality of Moderna Therapeutics
Follow Juan Andres:
About Moderna Therapeutics: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
George Lloyd
Executive Vice President, Investments and General Counsel of Royalty Pharma
Follow George Lloyd:
About Royalty Pharma: Industry leader in investing in marketed and late stage biopharmaceutical products
Jim Reddoch
Chief Scientific Officer, Executive Vice President, Head of Research and Investments of Royalty Pharma
Jim Reddoch is the Chief Scientific Officer and EVP, Research & Investments, Royalty Pharma
Follow Jim Reddoch:
About Leukemia & Lymphoma Society, Memorial Sloan – Kettering Cancer Center, Royalty Pharma: Industry leader in investing in marketed and late stage biopharmaceutical products
Georgianna Harris
Vice President of Regulatory Affairs of Alkermes
Georgianna Harris leads the regulatory affairs department at Alkermes. In this role, Dr. Harris provides regulatory strategy and guidance for development candidates and commercial products. Prior to joining Alkermes, Dr. Harris spent 25 years at Merck, in positions of increasing responsibility spanning laboratory research and regulatory affairs. During her tenure with Merck’s regulatory affairs organization, Dr. Harris oversaw global development, registration and post-registration activities for multiple small-molecule and biologic medicines for obesity, bone, oncology, diabetes and women’s health indications. Dr. Harris received a Bachelor of Science degree from Boston College and a Ph.D. in biochemistry from the University of Wisconsin. She was subsequently a postdoctoral research fellow at the Massachusetts Institute of Technology, in the Department of Chemistry.
Follow Georgianna Harris:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Mike Landine
Senior Vice President of Corporate Development of Alkermes
Mike Landine oversees Alkermes’ corporate development activities. Prior to leading corporate development, Mr. Landine served as Chief Financial Officer and Treasurer of Alkermes from March 1988 until June 1998. Mr. Landine is a member of the Board of Directors of Kopin Corporation, a publicly traded manufacturer of components for electronic products. He also previously served on the Board of Directors of GTC Biotherapeutics, a biotechnology company, from 2005 to 2010. Mr. Landine received a Bachelor of Science degree in accounting from Bentley University and is a Certified Public Accountant.
Follow Mike Landine:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Blair Jackson
Vice President of Business Development of Alkermes
Blair Jackson leads business development at Alkermes, encompassing licensing efforts, new product evaluation and alliance management. Since joining Alkermes in 1999, Mr. Jackson has served in various roles within the company in both a scientific and corporate capacity. Mr. Jackson also serves on the board of Civitas Therapeutics, a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies. Mr. Jackson received a Bachelor of Arts degree in biochemistry from the University of Calgary, a Bachelor of Arts in chemical engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in chemical engineering practice from the Massachusetts Institute of Technology.
Follow Blair Jackson:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Madeline Coffin
Vice President of Human Resources of Alkermes
Madeline Coffin leads Alkermes’ human resources team, with responsibility for global compensation and benefits, talent acquisition, employee engagement and growth and organization development. Ms. Coffin has held a number of senior human resource positions at companies including Analog Devices, Sun Microsystems, Wang Software and Bay Networks. Prior to joining Alkermes, she founded her own company, which focused on the strategic human resource needs of growing companies for clients in a broad range of industries. Ms. Coffin holds a Bachelor of Arts degree from Penn State University and a Master of Industrial and Labor Relations from Cornell University.
Follow Madeline Coffin:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Michael Mondo
Vice President of Sales of AeroSafe Global
Follow Michael Mondo:
About AeroSafe Global: AeroSafe Global develops aerogels used in various transport, biomedical, pharmaceutical, and other temperature-sensitive products.
Patricia Hurter
Senior Vice President, Pharmaceutical & Preclinical Sciences of Vertex Pharmaceuticals
Hurter joined Vertex in 2004 as Head of Formulation Development, became the Vice President of Pharmaceutical Development in 2006, and is currently the Senior Vice President of Pharmaceutical and Preclinical Sciences. The scope of her responsibilities include Pharmaceutical Development (development of chemical processes for drug substance manufacture as well as drug product formulation and process development, and associated characterization methods for activities from the discovery phase through to validation for commercial manufacturing), DMPK (preclinical drug metabolism and pharmacokinetics) and drug safety evaluation. Prior to joining Vertex, Dr. Hurter was Director of Formulation Development at Merck from 2000 to 2004. Before joining the pharmaceutical industry, Dr. Hurter worked in the paper industry for 8 years where she studied the microstructure of paper and its effects on end use performance. Dr. Hurter has a Ph.D. in Chemical Engineering from MIT, an M.S. in Mechanical Engineering from West Virginia University and a B.Sc. in Chemical Engineering from the University of Natal, Durban, South Africa.
Follow Patricia Hurter:
About Lyndra Therapeutics, Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Amit K. Sachdev
Executive Vice President, Chief Patient Officer. and Chief of Staff of Vertex Pharmaceuticals
Follow Amit K. Sachdev:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
David Altshuler
Executive Vice President, Global Research and Chief Scientific Officer of Vertex Pharmaceuticals
Dr. Altshuler is a Professor of Genetics and Medicine at Harvard Medical School, where he has served on the faculty since 2000. He is also one of the four founding members of the Broad Institute of Harvard University and the Massachusetts Institute of Technology. Trained as a clinical endocrinologist and a human geneticist, Dr. Altshuler’s clinical work is focused on characterizing patterns of variation in human genetics and applying this information to help isolate the genetic contribution to common diseases, including type 2 diabetes, cardiovascular disease and cancer. Through his work with multiple public-private partnerships, including the SNP Consortium, the International Haplotype Map Project and the 1000 Genomes Project, Dr. Altshuler has helped further the scientific community’s understanding of DNA sequence variation in the human genome and its contribution to the development of specific diseases. At the Broad Institute, he has directed its Program in Medical and Population Genetics since 2003 and has served as Chief Academic Officer since 2009. He is also on the faculty of Massachusetts General Hospital’s Department of Molecular Biology, the Diabetes Unit of the Department of Medicine and the Center for Human Genetic Research. Since 2012, he has served as Adjunct Professor of Biology at MIT. Dr. Altshuler has received numerous awards for his research and clinical activities related to human genetics, including the Stephen Krane Award from Massachusetts General Hospital, which recognized him as the Department of Medicine’s top young investigator, the 2011 Curt Stern Award of the American Society of Human Genetics given for outstanding scientific achievements in the last 10 years and the Richard and Susan Smith Pinnacle Award of the American Diabetes Association, which recognized his research into the contributing genetic cause of diabetes. He is a member of the American Society for Clinical Investigation, the Association of American Physicians and the US Institute of Medicine. He has served on advisory boards for many leading institutions, government organizations. Dr. Altshuler received his B.S. from the Massachusetts Institute of Technology, a Ph.D. from Harvard University and his M.D. from Harvard Medical School. He completed his internship, residency and clinical fellowship training at Massachusetts General Hospital.
Follow David Altshuler:
About Harvard Medical School, Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Michael Parini
Executive Vice President & Chief Legal and Administrative Officer of Vertex Pharmaceuticals
Mr. Parini is the Executive Vice President and Chief Legal and Administrative Officer at Vertex. He serves on the company’s Executive Committee and oversees the Legal, Compliance, Quality, Corporate Communications and Human Resources functions. Mr. Parini joined Vertex in 2016 after more than a decade at Pfizer Inc. where he served in multiple leadership roles within the company’s global legal team, including Senior Vice President and Associate General Counsel. He was responsible for the strategic management of Pfizer’s global litigation activities, including civil, intellectual property, government and employment litigation. He also served as Chief Counsel for multiple key business units within Pfizer, advising Pfizer’s leadership team on business issues related to investment decisions, patent disputes, global pricing strategies and commercial operations activities, among other responsibilities. Prior to Pfizer, Mr. Parini served as a healthcare attorney at Akin, Gump, Strauss, Hauer & Feld, L.L.P. in Washington, D.C., where he provided legal counsel on federal and state regulatory and policy issues. Mr. Parini is a member of the New York and District of Columbia bars. He received a B.S. in American government from Georgetown University and a law degree from Georgetown University Law.
Follow Michael Parini:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Paul Negulescu
Vice President of Vertex Pharmaceuticals
Paul Negulescu is the Senior Vice President and Site Head of San Diego Research. He’s been leading Vertex’s San Diego research location since 2003, the site that discovered Vertex’s medicines that treat the underlying cause of cystic fibrosis. Prior to joining Vertex, Dr. Negulescu was Senior Vice President of Discovery Biology and a member of the executive team at Aurora Biosciences. When Vertex acquired Aurora, he was responsible for integrating Aurora’s research into Vertex. Dr. Negulescu received both his B.S. and Ph.D. from U.C. Berkeley in Physiology and carried out post-doctoral work at U.C. Berkeley and U.C. Irvine in the areas of ion channel biophysics and immunology.
Follow Paul Negulescu:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Stephanie Franklin
Senior Vice President & Chief Human Resources Officer of Vertex Pharmaceuticals
Stephanie Franklin is the Senior Vice President and Chief Human Resources Officer (CHRO) at Vertex. She oversees all global aspects of human resources, including Talent Acquisition, Total Rewards, Global Organization & Leadership Development, HR Business Partners, Engagement and Diversity & Inclusion. Prior to joining Vertex in August of 2017, Stephanie was SVP, Global Human Resources at Nuance Communications where she was responsible for the HR Business Partner & Global HR Operations functions, Talent & Organizational Development and M&A. Before Nuance, Stephanie was the Vice President of Talent & Integrated HR Solutions at Blue Cross Blue Shield of Massachusetts and spent twelve years at Procter & Gamble. Stephanie is a business-focused, results oriented executive with over 20 years of experience in diverse industries and geographies who invests in designing & implementing successful HR strategies that enable organizations to achieve their unique potential. She is a leader in the community as Board Member and President of the Human Resources Leadership Forum (HRLF), a member and former Board Chair of the Boston-Manchester March of Dimes, and a member of the Bottom Line Massachusetts Regional Advisory Board. Stephanie was also co-founder & leader of the Procter & Gamble Boston Women’s Network, a senior mentor for the Women Unlimited Leadership Development Program, and Vice Chair of the United Way of Massachusetts Bay Healthy Childhood Development Initiative.
Follow Stephanie Franklin:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Damian Wilmot
Senior Vice President, Chief Risk and Compliance Officer of Vertex Pharmaceuticals
Mr. Wilmot is the Senior Vice President, Chief Risk and Compliance Officer at Vertex. He is responsible for leading the company’s Global Compliance (the Office of Business Integrity & Ethics), Global Litigation & Enterprise Risk Management, and Quality Assurance organizations. Before taking on his current role in 2017, Mr. Wilmot was the chief litigation counsel and also served as the company’s interim head of Compliance and interim head of Human Resources. His previous professional experience includes serving as the chief litigation counsel for another global pharmaceutical company and as a litigation partner with Goodwin Procter LLP. Mr. Wilmot previously was an Assistant United States Attorney in the District of Massachusetts and worked as a judicial law clerk on the State of Connecticut Supreme Court. He has served on the boards and advisory committees of numerous nonprofit, civic, and for-profit organizations, including the Massachusetts Judicial Nominating Commission (by gubernatorial appointment), the John F. Kennedy Library Foundation, and the Boys and Girls Club of Boston. In 2010, the Boston Business Journal recognized him as one of Boston’s outstanding business leaders under the age of 40. He has also been honored as one of Boston’s most influential people of color in healthcare and life sciences. Mr. Wilmot is a graduate of Trinity College in Hartford, Connecticut, and Suffolk University Law School in Boston.
Follow Damian Wilmot:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Mark Bunnage
Senior Vice President & Site Head, Boston Research of Vertex Pharmaceuticals
Dr. Bunnage joined Vertex in 2016 as Senior Vice President and Site Head for Boston Research. He oversees preclinical research from project initiation through to the identification of new candidate medicines. His team works on a number of serious diseases, including adrenoleukodystrophy, alpha-1 antitrypsin deficiency and sickle cell. Prior to joining Vertex, Dr. Bunnage spent 20 years at Pfizer, Inc., where he held a variety of roles within Medicinal Chemistry. From 1996 to 2011, Dr. Bunnage was based at Pfizer’s research site in the U.K. where he became Head of Medicinal Chemistry, Sandwich Laboratories. In 2011, he was appointed Vice President, Worldwide Medicinal Chemistry, and relocated to Cambridge, Massachusetts where he worked until 2016. Dr. Bunnage studied chemistry at the University of Durham and conducted postgraduate research with Professor S G Davies at the University of Oxford. He then moved to The Scripps Research Institute in La Jolla, California to work with Professor K C Nicolaou as a NATO postdoctoral fellow. Dr. Bunnage has broad interests in Drug Discovery and is an author or inventor on over 50 publications and patents. He is a Fellow of the Royal Society of Chemistry and a visiting Professor in Chemistry at the University of Oxford.
Follow Mark Bunnage:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Lara Abbaschian
Vice President of Lightstone Ventures
Follow Lara Abbaschian:
About Lightstone Ventures: Lightstone Ventures is a leading global venture capital firm.
Anna Turetsky
Vice President of Lightstone Ventures
Anna is an Associate at Lightstone Ventures (LSV), where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Boston office. Before joining Lightstone, Anna was an Analyst at Fletcher Spaght Inc., a healthcare strategy consulting firm in Boston. While at Fletcher Spaght, she advised clients in the medical device, biopharmaceutical, and healthcare IT sectors. Anna’s projects included researching and presenting market growth stories for public M&A transactions, supporting private equity due diligence for device deals, and developing best practices and strategy for a first-time life science venture fund in Canada. Anna holds a PhD from Harvard University, which she completed under the guidance of Professor Ralph Weissleder, Director of the Center for Systems Biology at Massachusetts General Hospital. Her interdisciplinary research combined chemical biology, engineering, and translational medicine to develop novel cancer diagnostics. While at Harvard, Anna was a National Science Foundation Graduate Research Fellow, an Early Technology Assessment Fellow at the Harvard Office of Technology Development, and held leadership positions in several career development-focused student groups. She also completed life science and corporate finance coursework at MIT Sloan School of Management and Harvard Business School. Anna’s additional work experience includes an internship with Siemens Venture Capital and consulting for Innotrove, LLC, an advisor to Merck’s MRL Ventures.
Follow Anna Turetsky:
About Lightstone Ventures: Lightstone Ventures is a leading global venture capital firm.
Kendall Forbes
Co-Founder & Executive Vice President, Operations & Sales of Guardian Pharmacy
EVP of Sales and Operations, and Founder of Central Pharmacy Services, Inc. Responsible for management of all field business units. Developed evolving structures and systems to leverage organizational skills in rapid growth entrepreneurial environment. Launched 37 greenfield start-up pharmacies, and integrated 8 acquisitions. Owner, Baton Rouge Central Pharmacy. Established and operated highly successful and profitable nuclear pharmacy. Recognized opportunity for building a larger company leveraging the service model so successfully employed in Baton Rouge market.
Follow Kendall Forbes:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Alex Ferguson
Vice President, Business Development of Guardian Pharmacy
Follow Alex Ferguson:
About Guardian Pharmacy, Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
David Morris
Executive Vice President & Chief Financial Officer of Guardian Pharmacy
CFO, Central Pharmacy Services, joining shortly after inception to build the central support and financial structure necessary to serve the dispersed, autonomous business units in a rapid growth entrepreneurial environment. Organizational units included accounting, information systems, human resources, M&A/business development, and administrative services. President, PBM Div., Complete Health. Established and operated Rx Management, a subsidiary PBM division of HMO Complete Health, which provided prescription drug management services to parent HMO’s/PPO’s and other Fortune 500 self-funded employer groups. C.P.A., Auditor, EY.
Follow David Morris:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Gail Mays Young
Vice President of Human Resources of Guardian Pharmacy
Director, Human Resources, Central Pharmacy Services 1994 – 2004; Sr. Professional Human Resources certification, 20+ years’ progressive management experience in international shipping and logistics and travel management. Joined Guardian in 2004.
Follow Gail Mays Young:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Robert Weir
Vice President of Operations & Regulatory Support of Guardian Pharmacy
B.S. in Pharmacy, St. Louis College of Pharmacy. Bob is a pharmacy management professional with a proven track record of successful leadership for multi-facility pharmacy locations. Before joining Guardian in 2015, Bob served as vice president of operations in the LTC division at Omnicare. Prior to Omnicare, Bob was responsible for operations at Continuing Care Rx. Bob also served for 12 years with Kindred Pharmacy Services (KPS), ultimately serving as senior vice president of operations until KPS merged with Pharmerica in 2007.
Follow Robert Weir:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Will Mudd
Vice President of Controller of Guardian Pharmacy
Follow Will Mudd:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Rich Eakins
Vice President of Sales of Guardian Pharmacy
Follow Rich Eakins:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Doug Towns
Vice President, General Counsel & Senior Compliance Officer of Guardian Pharmacy
B.A. in Political Science and Philosophy, Emory University; J.D., University of Virginia School of Law; Doug and Guardian’s executive team have a long-standing working partnership, dating back to 1995. While in private practice, Doug had spent nearly twenty years as a Partner with Jones Day in Atlanta. Joined Guardian in 2016.
Follow Doug Towns:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Chad Downey
Vice President of Treasurer & Internal Audit of Guardian Pharmacy
Follow Chad Downey:
About Guardian Pharmacy: Guardian Pharmacy is a pharmacy company provide outstanding client service to long-term care facilities.
Mike Browder
Executive Vice President & CFO of RCCH HealthCare Partners
Mike Browder served as Executive Vice President and CFO for RegionalCare since 2011. Mike also led Essent Healthcare as CEO for four years. Mike previously served as Senior Vice President and Chief Financial Officer for TMC HealthCare, Tucson Arizona, for two years where he was responsible for the financial aspects of all TMC HealthCare companies, including the Tucson Medical Center. From 1993 to 1999, Mike served as Vice President of Operations Finance for Health Management Associates, Inc. Mike began his career in the Atlanta office of Ernst & Young where he audited and consulted with a broad array of healthcare-related companies. Mike currently serves on the Board of Directors of the Federation of American Hospitals. Mike is a member of the American Institute of Certified Public Accountants, the Tennessee Society of Certified Public Accountants, Financial Executives Institute and an advanced member of the Healthcare Financial Management Association. Mike earned a B.B.A in accounting from the University of Georgia’s J.M. Tull School of Accounting.
Follow Mike Browder:
About RCCH HealthCare Partners: RCCH HealthCare Partners provides healthcare services.
Shankar Hariharan
Executive Vice President & Chief Scientific Officer of Amneal Pharmaceuticals
Dr. Hariharan holds Bachelors and Ph.D. degrees in Pharmacy. After 19 years successfully leading branded and generic divisions of two top pharmaceutical companies and a clinical research organization, in 2006 he started his own dermatologic pharmaceutical R&D company. Joining Amneal in 2010, Dr. Hariharan oversees all R&D, Regulatory Affairs and Specialty Pharmaceuticals operations.
Follow Shankar Hariharan:
About Amneal Pharmaceuticals: Amneal Pharmaceuticals manufactures, markets and/or distributes more than 88 drugs in the United States.
Joseph Todisco
Senior Vice President, Global Strategy & Operations of Amneal Pharmaceuticals
Joe brings to Amneal a wealth of knowledge and experience in the areas of business development, strategy and commercial operations. He has held senior leadership positions with both U.S. based and global generic pharmaceutical companies, and over the last decade, has taken a lead role in completing more than a hundred transactions. Joe holds a BA in Economics and an MBA in Finance.
Follow Joseph Todisco:
About Amneal Pharmaceuticals: Amneal Pharmaceuticals manufactures, markets and/or distributes more than 88 drugs in the United States.
Candis Edwards
Senior Vice President, Regulatory Affairs of Amneal Pharmaceuticals
Follow Candis Edwards:
About Amneal Pharmaceuticals: Amneal Pharmaceuticals manufactures, markets and/or distributes more than 88 drugs in the United States.
Jim Luce
Executive Vice President, Sales & Marketing of Amneal Pharmaceuticals
Jim brings 30+ years of Fortune-100-level sales and marketing leadership, strategic planning and organizational development experience to Amneal. His unique approach to driving customer value and focusing on mutual value creation with accounts continue as key factors in growing businesses well ahead of industry pace.
Follow Jim Luce:
About Amneal Pharmaceuticals: Amneal Pharmaceuticals manufactures, markets and/or distributes more than 88 drugs in the United States.
Narendra Lalwani
Executive Vice President of R & D and Chief Operating Officer of Esperion
Narendra Lalwani is Executive Vice President, R & D, and Chief Operating Officer. Prior to joining Esperion, Narendra was Chief Scientific Officer at Cerenis Therapeutics from 2007 to 2014 where he led R&D activities for the company. Previously, Narendra was Vice President of Drug Safety at the original Esperion until its acquisition by Pfizer. Prior to Esperion, Narendra held various positions of increasing responsibility in the Department of Pathology and Experimental Toxicology at Warner-Lambert/Parke-Davis. Narendra is a Fellow of American Heart Association (FAHA) and a diplomate of the American board of Toxicology (DABT).Narendra earned a Ph.D. in Biophysics from the University of Bombay (India) and an MBA from the University of Michigan, Ross School of Business.
Follow Narendra Lalwani:
About Esperion: Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases.
Paul Cossum
Executive Vice President of Research & Development of ESSA Pharma
Paul Cossum has served as the Executive Vice President of Research & Development of ESSA since April 2014. He has almost 30 years of biotechnology industry experience in drug development, both in scientific and management roles. Prior to joining ESSA, he served as President of the Texas BioAlliance, CEO of Proacta, EVP of Development at NewBiotics, VP of Preclinical Development at Aronex Pharmaceuticals, and Director of Preclinical Development at ISIS Pharmaceuticals. Paul began his scientific career at Genentech, Inc. He serves as a member of the board of directors at Pivotal BioSciences, Inc. He received his Doctorate from the School of Pharmacy, University of Tasmania in Australia. He has about 50 scientific papers published in peer-reviewed journals.
Follow Paul Cossum:
About ESSA Pharma: ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Jeffrey Sherman
Executive Vice President, Development, Manufacturing, and Regulatory Affairs, Chief Medical Officer of Horizon Pharma
Dr. Sherman has served as our executive vice president, development, manufacturing, and regulatory affairs, and chief medical officer since June 2011, as our executive vice president, development and regulatory affairs and chief medical officer since our inception in March 2010 and as the executive vice president, development and regulatory affairs and chief medical officer of Horizon Pharma USA since June 2009. From June 2009 through June 2010, Dr. Sherman served as president and board member of the Drug Information Association (DIA), a nonprofit professional association of members who work in government regulatory, academia, patient advocacy and the pharmaceutical and medical device industry. Dr. Sherman isa former president of DIA and serves as DIA liaison to the Clinical Trial Transformation Initiative (CTTI) a public-private partnership founded by the US Food and Drug Administration and Duke University to improve the quality and efficiency of clinical trials. He also serves on the Board of Advisors of the Center for Information and Study on Clinical Research Participation (CISCRP) a nonprofit organization dedicated to educating and informing the public, patients, medical/research communities, the media and policy makers about clinical research and the role each party plays in the process. He is an adjunct assistant professor of medicine at the Northwestern University Feinberg School of Medicine and is a member of a number of professional societies, as well as a diplomat of the National Board of Medical Examiners and the American Board of Internal Medicine. From August 2007 through June 2009, Dr. Sherman served as senior vice president of research and development and chief medical officer at IDM Pharma, which was acquired by Takeda in 2009. From June 2007 through August 2007, he served as vice president of clinical science at Takeda Global Research and Development. From September 2000 through June 2007, Dr. Sherman served as chief medical officer and executive vice president at NeoPharm, Inc., a biopharmaceutical company. From October 1992 through August 2000, Dr. Sherman served as director, senior director and executive director of clinical research, and was head of oncology global medical operations at Searle/Pharmacia, or Searle, a pharmaceutical company. Prior to joining Searle, Dr. Sherman worked in clinical pharmacology and clinical research at Bristol-Myers Squibb Company, a biopharmaceutical company. Dr. Sherman received his medical degree from the Rosalind Franklin University/Chicago Medical School. He completed an internal medicine internship, residency and chief medical residency at Northwestern University, as well as fellowship training at the University of California, San Francisco (UCSF). Dr. Sherman was also a research associate at the Howard Hughes Medical Institute at UCSF.
Follow Jeffrey Sherman:
About Horizon Pharma: Horizon Therapeutics focuses on the development of prescription drugs for mild to moderate pain relief and arthritis.
Michael J. Harrington
Senior Vice President & General Counsel of Eli Lilly
Mike Harrington is senior vice president and general counsel for Eli Lilly and Company. Since joining Lilly in 1991 as an attorney in product liability litigation, Mike has served in a number of other business and legal positions, including managing director of the New Zealand affiliate and as associate general counsel for Lilly’s operations in the Asia-Pacific region. Mike most recently held the role of vice president and deputy general counsel of global pharmaceutical operations. In this capacity, he was responsible for legal issues related to Lilly’s five global business units. Before joining Lilly, Mike was a litigator at the law firm of Baker & Daniels in Indianapolis. Mike earned a bachelor’s degree in English from Albion College and a law degree from the Columbia University School of Law. Mike currently serves as the board chair for the Indiana Repertory Theatre and the co-chair of the Civil Justice Reform Group (CJRG). He is also a member of the board of trustees and executive committee of Albion College.
Follow Michael J. Harrington:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Pandu Kulkarni
Vice President, Biometrics of Eli Lilly
Pandu works at Eli Lilly developing and executing enterprisewide analytics strategy, in addition to leading the global biometrics and advanced analytics group. He is the Chief Analytics Officer.
Follow Pandu Kulkarni:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Stephen F. Fry
Senior Vice President, Human Resources and Diversity of Eli Lilly
Steve Fry is senior vice president, human resources and diversity, for Eli Lilly and Company. Since joining Lilly in 1987 as a scientific systems analyst in Lilly Research Laboratories, Steve has held a range of roles in information technology and human resources. Following a series of managerial assignments, Steve served as human resources director for Lilly’s U.K. affiliate and then as executive director of human resources for the U.S. affiliate. In 2004 he was named managing director of the Australian affiliate, returning to the U.S. in 2007 to provide HR leadership for the global sales and marketing organization before accepting the role of vice president supporting the Lilly Bio-Medicines and Emerging Markets business units. He assumed his current role in 2011. Steve earned his bachelor’s degree in information systems from the University of Indianapolis. Steve serves on the board of trustees at the University of Indianapolis and
Follow Stephen F. Fry:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Susan Mahony
Senior Vice President & President, Lilly Oncology of Eli Lilly
Sue Mahony is a senior vice president of Eli Lilly and Company and president of Lilly Oncology. Sue joined Lilly in 2000 after more than ten years in sales and marketing roles in the United Kingdom and Europe in oncology, hematology, and cardiovascular medicine for Schering-Plough, Amgen, and Bristol-Myers Squibb. At Lilly, Sue has worked in product development, Six Sigma, marketing, and general management roles. After leading Lilly’s operations in Canada, Sue was appointed senior vice president of human resources and diversity, before assuming her current role in 2011. Sue earned a bachelor’s degree in pharmacy from Aston University in the U.K., and a Ph.D. in pharmacy in Aston’s Cancer Research Campaign’s experimental chemotherapy group. She also earned a master’s degree in business administration from the London Business School. In 2012, Sue received an honorary doctorate from Aston University.
Follow Susan Mahony:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Fionnuala M. Walsh
Senior Vice President, Global Quality of Eli Lilly
Fionnuala Walsh is senior vice president of global quality for Eli Lilly and Company. Fionnuala joined Lilly in 1988 at the manufacturing site in Kinsale, Ireland, where she held roles in technical services, project outsourcing, new-product introductions, and laboratory analytics. Fionnuala also held management positions in quality and manufacturing science and technology before she was appointed global quality leader in 2002 and vice president for global quality operations in 2005. She has served as senior vice president of global quality since 2007. Fionnuala earned her bachelor’s and doctoral degrees in chemistry from University College in Dublin, Ireland. She has served as a member of the Irish Council for Science, Technology, and Innovation and the API Committee of the Pharmaceutical Researchers and Manufacturers of America (PhRMA).
Follow Fionnuala M. Walsh:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
Barton R. Peterson
Senior Vice President, Corporate Affairs & Communications of Eli Lilly
Bart Peterson is senior vice president of corporate affairs and communications for Eli Lilly and Company. Before joining Lilly in 2009 in his current role, Bart served as managing director of Strategic Capital Partners, as a fellow with the Institute of Politics at Harvard University’s Kennedy School of Government, and as a distinguished visiting professor of public policy at Ball State University. From 2000 to 2007, Bart served two terms as mayor of Indianapolis, and in 2007 was president of the National League of Cities. In conjunction with Indiana University, Purdue University, Lilly, and the Central Indiana Corporate Partnership, Bart championed the creation of BioCrossroads, the Indiana life-sciences initiative. Prior to running for office, he was a member of Indiana Governor Evan Bayh’s leadership team, first as his advisor for environmental affairs and later as chief of staff. He also was an attorney with IceMiller in Indianapolis. Bart earned his bachelor’s degree from Purdue University and a law degree from the University of Michigan. Bart is a founding member and board chair of The Mind Trust, a non-profit organization promoting education reform. He also is a board member of the Regenstrief Foundation and Kite Realty Group, as well as a member of the Indiana University School of Public and Environmental Affairs Dean’s Council. In 2012, Bart was appointed by the U.S. Department of State to the Asia-Pacific Economic Cooperation (APEC) Business Advisory Council.
Follow Barton R. Peterson:
About Eli Lilly: Eli Lilly engages in the discovery, development, manufacture, and sale of products in pharmaceutical products business segment.
